ストックスクリーナーアプリを入手
3.619
3.45%
-0.131
前日終値:
$3.75
開ける：
$3.73
24時間の取引高:
135.67K
Relative Volume:
0.39
時価総額：
$220.74M
収益：
-
当期純損益:
$-40.33M
株価収益率:
-2.0218
EPS:
-1.79
ネットキャッシュフロー:
$-39.53M
1週間 パフォーマンス:
-4.97%
1か月 パフォーマンス:
-19.36%
6か月 パフォーマンス:
+36.63%
1年 パフォーマンス:
+116.81%
1日の値動き範囲:
$3.57
$3.7507
1週間の範囲:
$3.50
$3.97
52週間の値動き範囲:
$1.5199
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
名前
Eledon Pharmaceuticals Inc
セクター
電話
949-238-8090
住所
19800 MACARTHUR BLVD., IRVINE
ELDN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.625 | 220.74M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.40 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.98 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.50 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.87 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Guggenheim | Buy |
| 2022-05-13 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 開始されました | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Institutional investors in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) see US$25m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - GlobeNewswire
When Can You Hear Eledon's Latest Strategic Updates? Key Conference Appearance Scheduled - StockTitan
Eledon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Eledon Touts Tegoprubart Used in Pig Kidney Transplant - Orange County Business Journal
Before You Invest, Make Sure You Check This Eledon Pharmaceuticals Inc (NASDAQ: ELDN) Analysis - Stocks Register
Leerink Partnrs Has Pessimistic Outlook of ELDN Q4 Earnings - MarketBeat
Eledon's tegoprubart used in second pig-to-human kidney transplant - MSN
Leerink Partnrs Issues Negative Outlook for ELDN Earnings - Defense World
Eledon's tegoprubart used in second pig-to-human kidney transplant By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key - GlobeNewswire
Eledon announces tegoprubart use in transplant of pig kidney into human - TipRanks
Revolutionary Xenotransplant Success: Eledon Drug Enables Patient Freedom from Dialysis - StockTitan
FY2029 Earnings Estimate for ELDN Issued By Leerink Partnrs - Armenian Reporter
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Eledon CEO to Reveal Latest Biotech Developments at Major Guggenheim Conference - StockTitan
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business - Seeking Alpha
Guggenheim Initiates Eledon Pharmaceuticals at Buy With $9 Price Target -January 28, 2025 at 07:34 am EST - Marketscreener.com
Inspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Midday Stock Roundup: FivePoint Holdings Jumps 36% - Orange County Business Journal
Cantor Fitzgerald Comments on ELDN FY2025 Earnings - Defense World
Kidney Transplant Rejection Market Expected to Experience - openPR
Cantor Fitzgerald Weighs in on ELDN FY2025 Earnings - MarketBeat
Analyst Forecast For Eledon Pharmaceuticals Inc (NASDAQ: ELDN) - Stocks Register
Eledon Pharmaceuticals highlights recent business milestones, 2025 outlook - MSN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook - GlobeNewswire
Eledon's Tegoprubart Achieves Major Breakthrough in Kidney Transplant Trials, Secures $135M Funding - StockTitan
Geode Capital Management LLC Buys 33,569 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.9%Should You Sell? - MarketBeat
Eledon Pharmaceuticals adjusts CEO bonus structure - Investing.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Has Negative Outlook for ELDN Q4 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for ELDN Earnings - MarketBeat
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress - Investing.com Australia
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright - MarketBeat
FY2024 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - MarketBeat
Lifesci Capital Issues Optimistic Outlook for ELDN Earnings - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) 財務データ
収益
当期純利益
現金流量
EPS
5.68%
0.28%
大文字化:
|
ボリューム (24 時間):